Micot

Shaanxi Micot Pharmaceutical Technology Co., Ltd. was established in Xi'an in January 2007 and has now completed its layout in Xi'an, Suzhou, Beijing, Shanghai, Hong Kong, and the United States. The company is an innovative pharmaceutical technology enterprise focused on the research and development of new drugs, committed to becoming a leading forefront enterprise in the research and development of bifunctional and multifunctional specific peptide drugs, focusing on the research and development of new drugs for cardiovascular and cerebrovascular diseases, metabolic diseases, inflammation and pain related diseases. The company is committed to creating new drugs, saving lives, meeting unmet clinical needs, and using technological innovation to safeguard human health. As a platform based biotechnology company, Micot is committed to accelerating the innovation and development of a new generation of bispecific/multispecific peptide drugs worldwide. Our core product is currently undergoing phase III clinical trials. Since its establishment in 2007, we have focused on metabolic diseases (especially kidney related diseases) and cardiovascular and cerebrovascular diseases. As a global pioneer in proposing the concept of dual/multi specific peptide technology, and with a wide pipeline of candidate products entering clinical development, we have established a leading position in this field. We are committed to promoting peptide drugs as cornerstone therapies in multiple disease fields. With over ten years of experience in the research and development of peptide drugs, we have successfully established a comprehensive and integrated platform to support the innovation and industrialization of dual/multifunctional peptide candidate drugs. Up to now, we have developed a globally leading pipeline of dual/multifunctional peptides and innovative candidate drugs, including our core product MT1013, a world first peptide drug that targets both CaSR and OGP receptors. It is mainly developed for the treatment of SHPT and has the potential to be further developed for additional indications such as CKD-MBD with osteoporosis and SHPT without dialysis; And three key products, namely XTL6001, MT1002, and MT200605, as well as other candidate products.